We are live on ! Find out more
50.22 USD
-0.84
1.65%
At close Updated Sep 18, 4:00 PM EDT
Pre-market
After hours
50.22
0.00
0%
1 day
-1.65%
5 days
-0.14%
1 month
-1.82%
3 months
-0.89%
6 months
-3.53%
Year to date
1.19%
1 year
24.62%
5 years
3.42%
10 years
-7.22%
 

About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Employees: 66,841

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 58.7%
Neutral 30.2%
Negative 11.1%
Positive
MarketBeat
2 days ago
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
Neutral
Seeking Alpha
3 days ago
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
Zacks Investment Research
3 days ago
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
Positive
Reuters
3 days ago
GSK strikes up to $750 million deal for cancer-targeting drug
GSK said on Tuesday it had agreed a deal worth up to $750 million ​to buy a trispecific T cell-engager (TCE), a drug ‌designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.
GSK strikes up to $750 million deal for cancer-targeting drug
Neutral
Zacks Investment Research
4 days ago
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
Positive
MarketBeat
5 days ago
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through upcoming HIV patent expirations, Chief Financial Officer Julie Brown said during a company discussion.
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
Negative
Reuters
7 days ago
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
GSK said on Friday it will be shutting down ​a vaccine factory in Dresden, Germany, which ‌its website showed produces flu and hepatitis shots, in the summer of 2027.
GSK to shut vaccine factory in Germany, putting 641 jobs at risk
Positive
Zacks Investment Research
8 days ago
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
Neutral
Seeking Alpha
9 days ago
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
Neutral
Proactive Investors
14 days ago
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
GSK PLC's (LSE:GSK, NYSE:GSK)  experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says
Price charts implemented using Lightweight Charts™